XWXinle Wu

Xinle Wu

*This is an algorithmically generated author record based on publicly available information.

Xinle Wu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Charlise Giang

    USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA

    1 shared publication
  • Jieyi Meng

    Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

    1 shared publication
  • Mahmoud Ali Mohammad

    Department of Pediatrics, Children’s Nutrition Research Center, US Department of Agriculture/Agricultural Research Service, Baylor College of Medicine, Houston, USA

    1 shared publication
  • Yi Zhu

    USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

    1 shared publication
  • Zhenqi Liu

    Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, Va 22908, USA

    1 shared publication

Latest Publications

  • Open Access

    For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?

    by Charlise Giang, Jieyi Meng, Mahmoud Ali Mohammad, Zhenqi Liu, Xinle Wu, Yi Zhu

    Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have revolutionized the management of not only type 2 diabetes but also obesity. However, even with rapid therapeutic advances in GLP-1RAs, questions regarding the fundamental principles of GLP-1-mediated weight loss and the enhanced efficacy of next-generation therapies remain. In this comprehensive review article, we first examine the milestones of GLP-1, from its initial discovery and biological characterization to its successful translation into clinical therapy. Furthermore, this review highlights the latest clinical trial data, specifically HbA1c reduction, weight-loss efficacy, and safety profiles, while exploring current pipelines of major pharmaceutical companies. Additionally, we delineate the mechanistic principles underlying the efficacy of GLP-1 single- and multi-receptor agonists and address challenges in mitigating side effects of GLP-1RAs. Finally, we analyze the rapidly evolving landscape of next-generation, incretin-based combination therapies. With an abundance of GLP-1- related therapies already available or in development, we assess how future GLP-1 multi-receptor agonists can achieve enhanced efficacy and how leveraging weight-loss biology, such as set-point theory, can improve therapeutic outcomes.